吉西他滨联合顺铂对晚期肺鳞癌与肺腺癌的疗效分析

THE EFFICACY OF GEMCITABINE COMBINED WITH CISPLATIN FOR ADVANCED SQUAMOUS CELL CARCINOMA AND ADENOCARCINOM A OF THE LUNG CANCER

目的:比较吉西他滨联合顺铂对不同病理类型非小细胞癌的疗效差异。方法:选取晚期鳞癌组和腺癌患者作为研究资料,采用吉西他滨联合顺铂进行治疗,比较两组肿瘤缓解情况、安全性评价、生活质量及1年期随访生存率。结果:两组治疗后肿瘤体缓解情况比较差异无统计学意义(P>0.05);两组治疗中主要不良反应比较差异有统计学意义(P>0.05);两组生活质量改善情况比较差异无统计学意义(P>0.05);腺癌组随访1年生存率高于鳞癌组(P<0.05)。结论:联合用药对晚期肺鳞癌及肺腺癌的肿瘤缓解情况、安全性及生活质量改善情况相当,但联合用药对肺腺癌组1年期生存率的改善情况较好。

Objective：To compare the efficacy of gemcitabine combined with cisplatin tbr advanced squamous cell carcinoma and adenocarcinoma of lung cancer. Methods：Patients with advanced squamous cell carcinoma and adeuocarcinoma were chosed for research, and gemcitabine combined with eisplatin were used for the treatment. The tumor body remission, the safety evaluation, the quality of life and the one - year follow - up survival of the two groups were compared. Results ： After treatment, there was no significant difference of the tumor body remission between the two groups （ P 〉 0.05）. There was no significant difference of the main adverse e- vents between the two groups （ P 〉 0.05 ）. There was no significant difference of the quality of hfe between the two groups （ P 〉 0.05 ）. While the one - year follow - up survival rate of the adenocarcinoma group was higher than that of the squamous cell carcinoma group（ P 〈 0.05）. Conclusion： The combination therapy for advanced squamous cell carcinoma and lung adenocarcinoma has the same efficacy in relief from the tumor body, and the safety and quality beteveen life of the two groups are considerab. While the combined therapy could improve the one - year survival rate for the lung adenocarcinoma patients.